A live-attenuated RhCMV/SIV vaccine shows long-term efficacy against heterologous SIV challenge-Reference-Cited by-同舟云学术

A live-attenuated RhCMV/SIV vaccine shows long-term efficacy against heterologous SIV challenge

Published:2019-07-17 Issue:501 Volume:11 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Hansen Scott G.¹^ORCID,Marshall Emily E.¹^ORCID,Malouli Daniel¹^ORCID,Ventura Abigail B.¹,Hughes Colette M.¹,Ainslie Emily¹^ORCID,Ford Julia C.¹^ORCID,Morrow David¹^ORCID,Gilbride Roxanne M.¹,Bae Jin Y.¹^ORCID,Legasse Alfred W.¹^ORCID,Oswald Kelli²,Shoemaker Rebecca²,Berkemeier Brian²^ORCID,Bosche William J.²^ORCID,Hull Michael²,Womack Jennie¹^ORCID,Shao Jason³,Edlefsen Paul T.³^ORCID,Reed Jason S.¹,Burwitz Ben J.¹^ORCID,Sacha Jonah B.¹,Axthelm Michael K.¹^ORCID,Früh Klaus¹^ORCID,Lifson Jeffrey D.²^ORCID,Picker Louis J.¹^ORCID

Affiliation:

1. Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR 97006, USA.

2. AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.

3. Statistical Center for HIV/AIDS Research and Prevention, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.

Abstract

Highly attenuated pp71-deleted RhCMV/SIV vectors elicit immune responses that stringently protect 59% of vaccinated monkeys from SIV challenge.

Funder

NIH Office of the Director

National Cancer Institute

National Institute of Allergy and Infectious Diseases

Bill and Melinda Gates Foundation

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference46 articles.

1. Exploring the Potential Health Impact and Cost-Effectiveness of AIDS Vaccine within a Comprehensive HIV/AIDS Response in Low- and Middle-Income Countries

2. How Can We Get Close to Zero? The Potential Contribution of Biomedical Prevention and the Investment Framework towards an Effective Response to HIV

3. New Paradigms for HIV/AIDS Vaccine Development

4. Hidden Memories: Frontline Memory T Cells and Early Pathogen Interception

5. M. A. Jarvis S. G. Hansen J. A. Nelson L. J. Picker K. Früh Vaccine vectors using the unique biology and immunology of cytomegalovirus in Cytomegaloviruses: From Molecular Pathogenesis to Intervention M. J. Reddehase Ed. (Caister Academic Press 2013) vol. 2 chap. 21.

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cytomegalovirus;Remington and Klein's Infectious Diseases of the Fetus and Newborn Infant;2025

2. HIV Vaccine Development at a Crossroads: New B and T Cell Approaches;Vaccines;2024-09-12

3. Human Immunodeficiency Virus Vaccine;Infectious Disease Clinics of North America;2024-09

4. Mtbspecific HLA-E restricted T cells are induced duringMtbinfection but not after BCG administration in non-human primates and humans;2024-08-26

5. Viral escape mutations do not account for non-protection from SIVmac239 challenge in RhCMV/SIV vaccinated rhesus macaques;Frontiers in Immunology;2024-08-07